$-0.43 EPS Expected for Chimerix, Inc. (CMRX) on May, 8

April 16, 2018 - By Sonya McDaniel

Chimerix, Inc. (NASDAQ:CMRX) Corporate Logo
Big Money Sentiment increased to 1.18 in 2017 Q4. It has change of 0.10, from 2017Q3’s 1.08. The ratio increased due to Chimerix, Inc. positioning: 15 sold and 23 reduced. 18 funds amassed holdings and 27 increased holdings. Investors holded 33.85 million in 2017Q3 but now own 34.68 million shares or 2.45% more.
Bridgeway Mgmt Incorporated holds 239,200 shs or 0.01% of its capital. Geode Capital Management Limited Liability Com invested 0% in Chimerix, Inc. (NASDAQ:CMRX). Manufacturers Life Ins The owns 41,369 shs. Susquehanna Interest Gp Llp reported 41,142 shs. Bnp Paribas Arbitrage Sa accumulated 0% or 9,686 shs. Alliancebernstein L P invested 0% of its capital in Chimerix, Inc. (NASDAQ:CMRX). Renaissance Tech Ltd holds 259,152 shs. Rhumbline Advisers reported 0% of its capital in Chimerix, Inc. (NASDAQ:CMRX). Glenmede Na owns 6,992 shs. Moreover, Alps Incorporated has 0% invested in Chimerix, Inc. (NASDAQ:CMRX) for 52,132 shs. Barclays Public Limited Company holds 0% in Chimerix, Inc. (NASDAQ:CMRX) or 7,391 shs. Leisure Capital Mgmt stated it has 28,779 shs. Arrowmark Colorado Holdings Lc stated it has 0.13% of its capital in Chimerix, Inc. (NASDAQ:CMRX). Acadian Asset Mgmt Lc holds 0% of its capital in Chimerix, Inc. (NASDAQ:CMRX) for 60,411 shs. Us Financial Bank De invested in 35,000 shs.

Chimerix, Inc. (NASDAQ:CMRX)’s quarterly earnings will be reported On May, 8., according to RTT. Analysts predict $-0.43 EPS, which is $0.05 down or 13.16 % from 2017’s $-0.38 EPS. Last quarter $-0.41 EPS was reported. Analysts forecasts 4.88 % negative EPS growth this quarter. The stock decreased 1.78% or $0.09 during the last trading session, reaching $4.97.Chimerix, Inc. has volume of 69,397 shares. Since April 17, 2017 CMRX has declined 18.13% and is downtrending. CMRX underperformed the S&P500 by 29.68%.

Chimerix, Inc. (NASDAQ:CMRX) Ratings Coverage

Total analysts of 3 have positions in Chimerix (NASDAQ:CMRX) as follows: 1 rated it a “Buy”, 2 with “Sell” and 0 with “Hold”. The positive are 33%. Since February 2, 2018 according to StockzIntelligence Inc Chimerix has 4 analyst reports. The stock rating was downgraded by J.P. Morgan to “Sell” on Wednesday, February 14. On Wednesday, February 14 the firm earned “Underweight” rating by JP Morgan. The company rating was maintained by H.C. Wainwright on Friday, March 2.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States.The firm is worth $236.83 million. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients , as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.Last it reported negative earnings. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection.

Chimerix, Inc. (NASDAQ:CMRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.